Shu‐Pang Huang

Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors

Kurt A. Schalper, Michael Carleton, Ming Zhou et al. · Nature Medicine · 2020 · 515 citations · Full text

Inflammation, Cytokine, Immune Evasion +14

Pharmacodynamics, Safety, and Pharmacokinetics of BMS-663068, an Oral HIV-1 Attachment Inhibitor in HIV-1-Infected Subjects

Richard E. Nettles, Dirk Schürmann, Li Zhu et al. · The Journal of Infectious Diseases · 2012 · 105 citations · Full text

1422 POTENT VIRAL SUPPRESSION WITH ALL-ORAL COMBINATION OF DACLATASVIR (NS5A INHIBITOR) AND GS-7977 (NS5B INHIBITOR), +/− RIBAVIRIN, IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GT1, 2, OR 3

Mark Sulkowski, David Gardiner, E. Läwitz et al. · Journal of Hepatology · 2012 · 80 citations

Viral Hepatitis, +/− Ribavirin, Antiviral Drug Development +9

The cholesteryl ester transfer protein (CETP) TaqIB polymorphism in the cholesterol and recurrent events study: no interaction with the response to pravastatin therapy and no effects on cardiovascular outcome

Greetje J. de Grooth, Kim E. Zerba, Shu‐Pang Huang et al. · Journal of the American College of Cardiology · 2004 · 66 citations

Cardiovascular Disease, Medicine, Genetic Epidemiology +10

Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study of the Oral γ-Secretase Inhibitor BMS-708163 (Avagacestat): Tolerability Profile, Pharmacokinetic Parameters, and Pharmacodynamic Markers

Gary Tong, Junsheng Wang, Oleksandr Sverdlov et al. · Clinical Therapeutics · 2012 · 65 citations

Single-ascending Dose Study, Therapeutic Drug Monitoring, Pharmacology +9